BeStock  
Stocks › Biotechnology › IMVT

Immunovant IMVT

US equityMarket cap rank #1778Biotechnology
$31.77 −$0.75 (-2.31%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $31.51 -0.82%
Open$32.26
Prev close$32.52
Day range$31.61 – $32.77
Volume704.9K
Market cap$6.57B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±12.8%last 9 reports
Closed higher6 of 967% of the time
Best reaction+35.3%
Worst reaction-38.0%

Stock move on the day after each report

-38.0%2021/Q4+0.4%2022/Q1-8.2%2022/Q4-4.7%2025/Q2+0.1%2026/Q2+12.4%2026/Q3+35.3%2026/Q4+1.2%2027/Q1+15.1%2027/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2027/Q29 Nov 2026Pre Market±11.6%+15.13%Bigger than priced
2027/Q16 Aug 2026Pre Market±11.7%+1.17%Within range
2026/Q420 May 2026Pre Market±18.6%+35.26%Bigger than priced
2026/Q36 Feb 2026Pre Market±14.4%+12.43%Within range
2026/Q210 Nov 2025Pre Market±16.4%+0.09%Within range
2025/Q27 Nov 2024Pre Market±13.3%-4.74%Within range
2022/Q48 Jun 2022Pre Market±28.1%-8.20%Within range
2022/Q19 Aug 2021Pre Market±19.7%+0.39%Within range
2021/Q41 Jun 2021Pre Market±21.0%-37.99%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q2, ended Sep 2026

Revenue$0.00
Operating profit-$104.16M+21.0% YoY
Net profit-$97.25M+23.1% YoY
Diluted EPS-$0.47+35.6% YoY
Free cash flow-$83.22M+18.8% YoY
Operating cash flow-$83.22M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-111.1MDec '24$-106.4MMar '25$-120.6MJun '25$-126.5MSep '25$-110.6MDec '25$-147.9MMar '26$-153.2MJun '26$-97.2MSep '26

Profitability & balance sheet

Return on equity-86.5%
Return on assets-75.7%
Return on invested capital-91.2%
Current ratio7.31
Liabilities / assets13.7%
Cash & investments$722.27M
Net cash (debt)$722.27M

Discussion

No comments yet — be the first to weigh in on IMVT.

Sign in to join the discussion.

Scroll to Top